Orchard Therapeutics and Er-Kim Announce Partnership to Broaden Access to Libmeldy to Eligible Patients in Turkey and Certain Eurasian CountriesGlobeNewsWire • 10/07/24
Orchard Therapeutics Announces Multiple Presentations from across its Late-stage Neurometabolic Portfolio at SSIEM 2024GlobeNewsWire • 08/28/24
Orchard Therapeutics Celebrates Global Progress toward Advancing Newborn Screening for MLD on International Neonatal Screening DayGlobeNewsWire • 06/28/24
Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health ListGlobeNewsWire • 05/03/24
Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic LeukodystrophyGlobeNewsWire • 03/20/24
Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.GlobeNewsWire • 03/18/24
Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler SyndromeGlobeNewsWire • 02/05/24
Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposiumGlobeNewsWire • 02/02/24
Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to LibmeldyGlobeNewsWire • 01/25/24
Kyowa Kirin Successfully Completes Acquisition of Orchard Therapeutics, a Global Gene Therapy Leader for Rare DiseasesBusiness Wire • 01/24/24
Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseasesGlobeNewsWire • 01/24/24
Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLDGlobeNewsWire • 12/11/23
Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IHGlobeNewsWire • 11/30/23
ORCHARD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Orchard Therapeutics plc - ORTXBusiness Wire • 11/28/23
Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business AccomplishmentsGlobeNewsWire • 11/13/23
Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023GlobeNewsWire • 10/26/23
Orchard Therapeutics PLC Sponsored ADR (ORTX) Surges 96.0%: Is This an Indication of Further Gains?Zacks Investment Research • 10/06/23
Highly Rated Biotech Orchard Therapeutics Scores A Takeover, Shares Nearly DoubleInvestors Business Daily • 10/05/23